Characterization of Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma and Cases of Chronic Pancreatitis of Various Etiologies

Pancreatology ◽  
2017 ◽  
Vol 17 (3) ◽  
pp. S20
Author(s):  
Lena Haeberle ◽  
Katja Steiger ◽  
Anna Melissa Schlitter ◽  
Mert Erkan ◽  
Irene Esposito
PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e94357 ◽  
Author(s):  
Ole Helm ◽  
Ruben Mennrich ◽  
Domantas Petrick ◽  
Lisa Goebel ◽  
Sandra Freitag-Wolf ◽  
...  

Pancreatology ◽  
2013 ◽  
Vol 13 (1) ◽  
pp. e10
Author(s):  
Abasi Ene-Obong ◽  
Andrew J. Clear ◽  
Alan G. Ramsay ◽  
Hemant M. Kocher

Pancreatology ◽  
2012 ◽  
Vol 12 (5) ◽  
pp. e3-e4
Author(s):  
Christine Feig ◽  
James O. Jones ◽  
Richard J.B. Wells ◽  
David A. Tuveson ◽  
Douglas T. Fearon

2021 ◽  
Vol 10 ◽  
Author(s):  
Yang Wu ◽  
Chun Zhang ◽  
Kuirong Jiang ◽  
Jens Werner ◽  
Alexandr V. Bazhin ◽  
...  

Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells (PSCs), the major producers of extracellular matrix (ECM), drive the severe stromal/desmoplastic reaction in PDAC. Furthermore, the crosstalk among PSCs, pancreatic cancer cells (PCCs) as well as other stroma cells can establish a growth-supportive tumor microenvironment (TME) of PDAC, thereby enhancing tumor growth, metastasis, and chemoresistance via various pathways. Recently, targeting stroma has emerged as a promising strategy for PDAC therapy, and several novel strategies have been proposed. The aim of our study is to give a profound review of the role of PSCs in PDAC progression and recent advances in stroma-targeting strategies.


2018 ◽  
Vol 1 (1) ◽  
pp. AB025-AB025
Author(s):  
Kazuhiro Koikawa ◽  
Kenoki Ohuchida ◽  
Yohei Ando ◽  
Shin Kibe ◽  
Hiromichi Nakayama ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document